Chime Biologics Relisted in the Hurun Future Unicorns in the World 2023, Recognized by the Market for Growth
Article Date
August 17, 2023
This article is featured on another website.
Go to article
September 21, 2023
Inmagene announces formation of Celexor Bio based on its anti-ILT7 mAb with enhanced pDC depletion function
September 21, 2023
Inmagene announces formation of Celexor Bio based on its anti-ILT7 mAb with enhanced pDC depletion function
August 7, 2023
Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates
Company plans to initiate a Phase 2 SEISMiC extension study of istaroxime in early cardiogenic shock in Q3; Study start-up for a Phase 2 SCAI Stage C cardiogenic shock study underway Completed $12.4 million public offering including full exercise of overallotment option WARRINGTON, Pa. , Aug.
August 7, 2023
Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates
Company plans to initiate a Phase 2 SEISMiC extension study of istaroxime in early cardiogenic shock in Q3; Study start-up for a Phase 2 SCAI Stage C cardiogenic shock study underway Completed $12.4 million public offering including full exercise of overallotment option WARRINGTON, Pa. , Aug.